179 related articles for article (PubMed ID: 38113952)
21. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer.
Wang S; Liu Y; Xiao H; Chen Z; Yang X; Yin J; Li Y; Yuan C; Yan S; Chen G; Gao Q; Kong B; Sun C; Song K
Cell Death Dis; 2023 Nov; 14(11):775. PubMed ID: 38012150
[TBL] [Abstract][Full Text] [Related]
23. An acid-responsive MOF nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway.
Feng Z; Chen G; Zhong M; Lin L; Mai Z; Tang Y; Chen G; Ma W; Li G; Yang Y; Yu Z; Yu M
Biomaterials; 2023 Nov; 302():122333. PubMed ID: 37738743
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic regulation of pyroptosis in cancer: Molecular pathogenesis and targeting strategies.
Zhang RN; Jing ZQ; Zhang L; Sun ZJ
Cancer Lett; 2023 Oct; 575():216413. PubMed ID: 37769798
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
26. Pyroptosis Provides New Strategies for the Treatment of Cancer.
Jia Y; Wang X; Deng Y; Li S; Xu X; Qin Y; Peng L
J Cancer; 2023; 14(1):140-151. PubMed ID: 36605484
[TBL] [Abstract][Full Text] [Related]
27. Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy.
Li Y; Lv J; Shi W; Feng J; Liu M; Gan S; Wu H; Fan W; Shi M
Front Immunol; 2021; 12():710110. PubMed ID: 34421915
[TBL] [Abstract][Full Text] [Related]
28. The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles.
Hu Y; Liu Y; Zong L; Zhang W; Liu R; Xing Q; Liu Z; Yan Q; Li W; Lei H; Liu X
Cell Death Dis; 2023 Dec; 14(12):836. PubMed ID: 38104141
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
[TBL] [Abstract][Full Text] [Related]
30. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
31. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive characterization of pyroptosis phenotypes with distinct tumor immune profiles in gastric cancer to aid immunotherapy.
Huang K; Lin Y; Qiu G; Wang S; Feng L; Zheng Z; Gao Y; Fan X; Zheng W; Zhuang J; Luo F; Feng S
Aging (Albany NY); 2023 Aug; 15(16):8113-8136. PubMed ID: 37595258
[TBL] [Abstract][Full Text] [Related]
33. Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.
Zhang Q; Tan Y; Zhang J; Shi Y; Qi J; Zou D; Ci W
Front Immunol; 2022; 13():782982. PubMed ID: 35479097
[TBL] [Abstract][Full Text] [Related]
34. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
35. Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.
Berkel C; Cacan E
Inflammation; 2021 Dec; 44(6):2203-2216. PubMed ID: 34091823
[TBL] [Abstract][Full Text] [Related]
36. Role of Pyroptosis in Gynecological Oncology and Its Therapeutic Regulation.
Huang Y; Li R; Yang Y
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883480
[TBL] [Abstract][Full Text] [Related]
37. Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies.
Wang W; Zhang L; Sun Z
Cancer Biol Med; 2022 Jul; 19(7):948-64. PubMed ID: 35856558
[TBL] [Abstract][Full Text] [Related]
38. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
39. Crosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy.
Meybodi SM; Ejlalidiz M; Manshadi MR; Raeisi M; Zarin M; Kalhor Z; Saberiyan M; Hamblin MR
Crit Rev Oncol Hematol; 2024 May; 197():104340. PubMed ID: 38570176
[TBL] [Abstract][Full Text] [Related]
40. Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer.
Luo L; Wei Q; Xu C; Dong M; Zhao W
Front Immunol; 2022; 13():933703. PubMed ID: 36189269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
